CN105264382A - 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法 - Google Patents

基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法 Download PDF

Info

Publication number
CN105264382A
CN105264382A CN201480030240.4A CN201480030240A CN105264382A CN 105264382 A CN105264382 A CN 105264382A CN 201480030240 A CN201480030240 A CN 201480030240A CN 105264382 A CN105264382 A CN 105264382A
Authority
CN
China
Prior art keywords
her3
her2
amount
total
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030240.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·J·沃维博尔
J·W·温斯娄
L·D·艾力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CN105264382A publication Critical patent/CN105264382A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480030240.4A 2013-04-05 2014-04-07 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法 Pending CN105264382A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809083P 2013-04-05 2013-04-05
US61/809,083 2013-04-05
PCT/US2014/033208 WO2014165855A1 (en) 2013-04-05 2014-04-07 Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation

Publications (1)

Publication Number Publication Date
CN105264382A true CN105264382A (zh) 2016-01-20

Family

ID=50686216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480030240.4A Pending CN105264382A (zh) 2013-04-05 2014-04-07 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法

Country Status (6)

Country Link
US (1) US20160041171A1 (https=)
EP (1) EP2981828A1 (https=)
JP (1) JP6402173B2 (https=)
CN (1) CN105264382A (https=)
CA (1) CA2908515A1 (https=)
WO (1) WO2014165855A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
US20190041389A1 (en) * 2015-02-13 2019-02-07 The University Of Queensland Methods for classifying tumors and uses therefor
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
WO2017161030A1 (en) * 2016-03-15 2017-09-21 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
KR20180117529A (ko) * 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
WO2019241599A1 (en) * 2018-06-14 2019-12-19 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541109A (zh) * 2001-08-09 2004-10-27 ���տƼ��ٽ�Э�� Her3活性抑制剂
US20080187948A1 (en) * 2002-05-21 2008-08-07 Monogram Biosciences Inc. Erbb heterodimers as biomarkers
WO2009068423A2 (en) * 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
CN102460152A (zh) * 2009-01-15 2012-05-16 美国控股实验室公司 通过测量Her-3确定患者反应的方法
CN102492039A (zh) * 2011-11-21 2012-06-13 无锡天演生物技术有限公司 全人源抗人her2单抗

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1989012232A1 (en) 1988-06-08 1989-12-14 London Diagnostics, Inc. Assays utilizing sensitizer-induced production of detectable signals
US4997928A (en) 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5654442A (en) 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ES2094795T3 (es) 1990-11-02 1997-02-01 Ici Plc Ftalocianinas polisustituidas.
JP2758730B2 (ja) 1991-04-25 1998-05-28 三菱電機株式会社 放電励起パルスレーザ発振装置
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993021230A1 (en) 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
CA2141451C (en) 1992-07-31 2003-10-07 John S. Pease Photoactivatable chemiluminescent matrices
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6191278B1 (en) 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
JP2006509183A (ja) 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
EP1613205B1 (en) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
JP2012515353A (ja) 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
EP2751562B1 (en) * 2011-09-02 2015-09-16 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541109A (zh) * 2001-08-09 2004-10-27 ���տƼ��ٽ�Э�� Her3活性抑制剂
US20080187948A1 (en) * 2002-05-21 2008-08-07 Monogram Biosciences Inc. Erbb heterodimers as biomarkers
WO2009068423A2 (en) * 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
WO2009068423A3 (en) * 2007-11-30 2009-07-16 Siemens Healthcare Diagnostics Method for predicting therapy responsiveness in basal like tumors
CN102460152A (zh) * 2009-01-15 2012-05-16 美国控股实验室公司 通过测量Her-3确定患者反应的方法
CN102492039A (zh) * 2011-11-21 2012-06-13 无锡天演生物技术有限公司 全人源抗人her2单抗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALI MUKHERJEE, ET AL.: "Profiling the HER3/PI3K Pathway in Breast Tumors Using Proximity-Directed Assays Identifies Correlations between Protein Complexes and Phosphoproteins.", 《PLOS ONE》 *

Also Published As

Publication number Publication date
EP2981828A1 (en) 2016-02-10
US20160041171A1 (en) 2016-02-11
JP2016517960A (ja) 2016-06-20
JP6402173B2 (ja) 2018-10-10
CA2908515A1 (en) 2014-10-09
WO2014165855A9 (en) 2014-11-27
WO2014165855A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CN102439452B (zh) 通过测量her-2表达确定患者应答的方法
US10416162B2 (en) Her2 diagnostic methods
JP6402173B2 (ja) Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
CN108780089B (zh) 评估细胞间的蛋白质相互作用的方法
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
US11579148B2 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
WO2007041502A2 (en) Methods for determining responsiveness to cancer therapy
US11401344B2 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20260125490A1 (en) Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160120